Please login to the form below
ICS
This page shows the latest ICS news and features for those working in and with pharma, biotech and healthcare.
Phase 3 trial of AstraZeneca and Avillion’s PT027 shows promise for asthma patients
During the trial, patients were randomised to receive either PT027 or albuterol rescue, in addition to their usually prescribed maintenance ICS, with or without additional controller medicines.
Latest news
-
FDA grants priority review for AZ, Amgen’s tezepelumab for asthma
In this trial, SoC was defined as medium- or high-dose inhaled corticosteroids (ICS) plus at least one additional controller medication, with or without oral corticosteroids (OCS).
-
AZ, Amgen file first-in-class asthma drug with the FDA
In this trial, SoC was defined as medium- or high-dose inhaled corticosteroids (ICS) plus at least one additional controller medication, with or without oral corticosteroids (OCS).
-
Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval for first-line NSCLC
An exploratory analysis showed that among these patients, the intracranial objective response rate (IC-ORR) was 82% in the Lorbrena arm compared to 23% in the Xalkori arm.
-
AZ, Amgen’s tezepelumab reduces asthma exacerbations in broad patient population
In this trial, SoC was defined as medium- or high-dose inhaled corticosteroids (ICS) plus at least one additional controller medication, with or without oral corticosteroids (OCS).
-
AZ, Amgen’s investigational asthma drug comes good in phase 3
The phase 3 NAVIGATOR trial evaluated tezepelumab plus standard of care, which included medium- or high-dose inhaled corticosteroids (ICS) plus at least one controller medication, with or without oral corticosteroids
More from news
Approximately 1 fully matching, plus 35 partially matching documents found.
Latest Intelligence
-
Improving cardiovascular disease care and awareness
guidelines. At this point, there is a need for the ICS, ICB and other health boards to implement these guidances much more rapidly.
-
Managing COPD: the 2023 GOLD report
With the 2023 Report, GOLD no longer encourages the use of a LABA/inhaled corticosteroid (ICS) combination in COPD.
-
Strictly personal: how to deliver 360-degree engagement to support your organisation’s agility and impact
This might include data such as their involvement in formulary committees, their profile within ICS steering groups and any clinical leadership roles they hold within place-based partnerships.
-
GSK forges ahead with its dynamic COPD and asthma portfolio
For instance, in the UK, US, Canada and Spain, the first treatment was an ICS/LABA, such Seretide or Symbicort, while in Germany it was a bronchodilator.
-
The roaring ‘20s and Generation Z
For instance, the draft NHS Standard Contract 2020/21, published in December 2019 will see NHS Trusts and CCGs being contractually obliged to work collectively as a single local ICS system, ... Over the next five years at least, campaigns and messaging
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest from PMHub
-
ICS/ICB leaders Penny Dash and Paul Miller announced as speakers for the NHS Transformation Symposium
Dr Penny Dash (Chair of North West London ICS). Paul Miller (Non-Executive Director [NED], North East Somerset, Swindon and Wiltshire ICB and NED, Salisbury NHS Foundation Trust). ... George Coxon (Chair of the South West Care Collaborative). Crystal
-
Mtech Access
We are Mtech Access, a global market access and health economics and outcomes research (HEOR) consultancy supporting top Pharmaceutical companies, Medtech innovators and the wider life sciences industry.
-
UNDERSTANDING THE ROLE OF PLACE WITHIN THE NEW NHS: FIVE THINGS INDUSTRY NEEDS TO KNOW
Indeed, analysis by the Health Service Journal shows there will be a total of 175 places within the 42 ICS areas in England. ... Some designated places in larger ICSs cover the same population size as a small ICS, for instance.
-
MISSION CRITICAL: HOW PHARMA CAN HELP THE NHS IMPROVE CARE FOR OLDER PEOPLE
for older patients in ICS five-year plan.
-
ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
Provider Collaboratives, Primary Care Networks and Place-Based Partnerships. Beneath them, there are further networks and entities responsible for delivering integrated services at different levels within the ICS. ... own formularies and ways of
More from PMHub
Approximately 3 fully matching, plus 23 partially matching documents found.
Subscribe to our email news alerts
- Contagious Conversations: Exploring Infectious Disease in the Digital Age
- Austrian State Secretary to speak at FlyPharma Europe 2023
- Further data for AstraZeneca/Daichii Sankyo’s Enhertu for breast cancer requested by NICE
- Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate
- EDX Medical Group develops multi-disease 'point-of-care' rapid tests for cancer, infections and cardiovascular conditions
- ScreenPoint Medical to showcase AI software at European scientific meeting
No results were found
PMHub
AMICULUM
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >300 healthcare communications professionals,...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
